Neuroscientific Biopharmaceuticals Limited Announces Chief Executive Officer Changes

Board of NeuroScientific Biopharmaceuticals Ltd. announced that Mr. Stephen Carter has been appointed as Chief Executive Officer (CEO), allowing Mr. Paul Rennie to step down as Interim Chief Executive Officer and remain as Non-executive Chair of the Board. Mr. Carter will assume the role on 11 September 2023. Stephen brings in excess of 30 years' broad experience in the Pharmaceucal and Medical Device industry.

He has held a variety of senior posions with mulnaonals (Pfizer, Pharmacia and Upjohn) and started up and ran a number of smaller private and publicly listed companies. Stephen has extensive contacts and experience in both the technical and business aspects of the pharmaceucal industry. Stephen brings broad experience in growing early-stage development companies, both listed and unlisted, being involved in a number of start-ups as CEO, Chairman and MD.

His experience covers strategic development, design and management of pre-clinical studies as well as human Phase 1, 2 and 3 clinical trials. He brings experience in investor and investment management, capital raising, business development and partnering as well as regulatory and corporate compliance across many global jurisdicons.